The Neuren Q3 2024 Daybue revenue update on this occasion did not include any useful commentary in relation to patients on therapy numbers as is their usual practice.The so called narrowing[effectively a downgrade] of net sales guidance for 2024 by US$20M suggests that patient numbers are not moving up greatly and that any Canadian revenue is not close.The $91.2M revenue for the quarter also missed the Zacks Consensus Estimate of $93.8 million as well their model estimate of $97.4 million. This position is only mentioned in view of the severe reaction of the Neuren share price to adverse Acadia missed revenue indications. Kens
NEU Price at posting:
$16.57 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)